The trial results are encouraging, with the highlight for Mainstay Medical being the 90 per cent of patients who report an improvement in quality of life after six months of using the surgically implanted device.

Anyone will chronic lower back pain will tell you just how disabling it can be. That’s why investors are excited by the prospects for a new approach b(...)

Mainstay Medical chief executive  Peter Crosby estimates that there is a potential market for its device of more than two million people in the US and Europe. Photograph: Nick Bradshaw

Irish company Mainstay Medical will seek regulatory approval in Europe for its chronic lower back pain device following clinical trial results that co(...)

Malin has decided to target the funding needs of privately held early-stage life sciences business.

The Elan gene pool delivers once again. It would be wrong to suggest that the business – since subsumed into generics and over-the-counter specialist (...)

Fountain Healthcare founders (from left) Dr Ena Prosser, Justin Lynch, Dr Manus Rogan and Aidan King. Photograph: Nick Bradshaw

Venture capital group Fountain Healthcare has raised €85 million in a second fund to drive investment in Europe’s life sciences sector.Ireland’s large(...)

Civitas is developing an inhaled form of the drug levadopa that is currently used by Parkinson’s patients in tablet form.

Irish private equity group Fountain Healthcare is one of the big winners following the sale of a company that has developed a experimental therapy fo(...)

Manus Rogan of Fountain Healthcare and Peter Crosby, chief executive of Mainstay Medical.

Back pain group Mainstay Medical has floated in Paris and Dublin in an IPO that values the early stage medical device company (...)

Mainstay Medical chief executive Peter Crosby.

Irish medical device company Mainstay Medical plans to raise up to €26.4 million in a stock market flotation (...)

 Peter Crosby, chief executive of Mainstay Medical. Photograph: Nick Bradshaw

Mainstay Medical, an Irish-based group focused on addressing chronic back pain, has announced it plans to float on the (...)

Genable Technologies founder and director Prof Jane Farrar. Photo: Aidan Crawley

Genable Technologies, a Dublin company targeting genetic diseases causing blindness, has announced a collaboration with US biopharma group Spar(...)

Trials are starting initially in Australia as the regulatory path there was considered quicker to negotiate, according to the company’s Australian chief executive, Peter Crosby.

It has taken three years to get a product to trials: Mainstay Medical hopes that within another two, it will have a device on the market in Eur(...)